Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MOXIFLOXACIN Cause Malignant neoplasm progression? 19 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Malignant neoplasm progression have been filed in association with MOXIFLOXACIN (Moxifloxacin Hydrochloride Tablets, 400 mg). This represents 0.1% of all adverse event reports for MOXIFLOXACIN.

19
Reports of Malignant neoplasm progression with MOXIFLOXACIN
0.1%
of all MOXIFLOXACIN reports
12
Deaths
13
Hospitalizations

How Dangerous Is Malignant neoplasm progression From MOXIFLOXACIN?

Of the 19 reports, 12 (63.2%) resulted in death, 13 (68.4%) required hospitalization, and 5 (26.3%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MOXIFLOXACIN. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does MOXIFLOXACIN Cause?

Drug hypersensitivity (2,013) Off label use (1,563) Dyspnoea (1,543) Drug ineffective (1,496) Vomiting (1,377) Pain (1,368) Asthma (1,342) Neuropathy peripheral (1,331) Rash (1,212) Pneumonia (1,172)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which MOXIFLOXACIN Alternatives Have Lower Malignant neoplasm progression Risk?

MOXIFLOXACIN vs MOXIFLOXACIN\MOXIFLOXACIN MOXIFLOXACIN vs MOXONIDINE MOXIFLOXACIN vs MS CONTIN MOXIFLOXACIN vs MULTAQ MOXIFLOXACIN vs MULTIHANCE

Related Pages

MOXIFLOXACIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression MOXIFLOXACIN Demographics